Literature DB >> 34580401

Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?

Shenmiao Yang1, Neil E Kay2, Min Shi3, Gert Ossenkoppele4, Roland B Walter5, Robert Peter Gale6.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34580401     DOI： 10.1038/s41375-021-01419-7

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  53 in total

Review 1.  Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment?

Authors:  Abraham M Varghese; Andy C Rawstron; Peter Hillmen
Journal:  Curr Hematol Malig Rep       Date:  2010-01       Impact factor: 3.952

Review 2.  Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

Authors:  Philip A Thompson; William G Wierda
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

Review 3.  Relevance of Minimal Residual Disease in the Era of Targeted Agents.

Authors:  Silvia Heltai; Paolo Ghia; Lydia Scarfò
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

Review 4.  Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.

Authors:  Carolyn Owen; Anna Christofides; Nathalie Johnson; Tatiana Lawrence; David MacDonald; Carol Ward
Journal:  Leuk Lymphoma       Date:  2017-05-16

Review 5.  The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?

Authors:  Sebastian Böttcher; Michael Hallek; Matthias Ritgen; Michael Kneba
Journal:  Hematol Oncol Clin North Am       Date:  2013-04       Impact factor: 3.722

6.  Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.

Authors:  Caroline Algrin; Jean-Louis Golmard; Mauricette Michallet; Oumedaly Reman; Anne Huynh; Aurore Perrot; Anne Sirvent; Adriana Plesa; Véronique Salaun; Marie-Christine Béné; Dominique Bories; Olivier Tournilhac; Hélène Merle-Béral; Véronique Leblond; Magali Le Garff-Tavernier; Nathalie Dhedin
Journal:  Eur J Haematol       Date:  2017-01-30       Impact factor: 2.997

Review 7.  Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.

Authors:  Ciprian Tomuleasa; Cristina Selicean; Sonia Cismas; Anca Jurj; Mirela Marian; Delia Dima; Sergiu Pasca; Bobe Petrushev; Vlad Moisoiu; Wilhelm-Thomas Micu; Anna Vischer; Kanza Arifeen; Sonia Selicean; Mihnea Zdrenghea; Horia Bumbea; Alina Tanase; Ravnit Grewal; Laura Pop; Carmen Aanei; Ioana Berindan-Neagoe
Journal:  Crit Rev Clin Lab Sci       Date:  2018-05-25       Impact factor: 6.250

8.  Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

Authors:  Philip A Thompson; Constantine S Tam; Susan M O'Brien; William G Wierda; Francesco Stingo; William Plunkett; Susan C Smith; Hagop M Kantarjian; Emil J Freireich; Michael J Keating
Journal:  Blood       Date:  2015-10-22       Impact factor: 22.113

9.  The total cellularity of the bone marrow in man.

Authors:  W J HARRISON
Journal:  J Clin Pathol       Date:  1962-05       Impact factor: 3.411

Review 10.  Measurable residual disease in the treatment of chronic lymphocytic leukemia.

Authors:  Takayoshi Uchiyama; Aki Yokoyama; Sadao Aoki
Journal:  J Clin Exp Hematop       Date:  2020-11-04
View more
  1 in total

1.  Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?

Authors:  Shenmiao Yang; Neil E Kay; Min Shi; Curtis A Hanson; Robert Peter Gale
Journal:  Leukemia       Date:  2022-09-13       Impact factor: 12.883
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.